1. Home
  2. Downgrades
  3. What’s Going On With RAPT Therapeutics Stock On Wednesday?

What’s Going On With RAPT Therapeutics Stock On Wednesday?

4
0

Tuesday, the FDA verbally notified RAPT Therapeutics Inc (NASDAQ:RAPT) that a clinical hold has been placed on the company’s Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma. 

The shares closed at $6.87 on Tuesday, sharply down from $25.97 at Friday’s close.

Wednesday, RAPT Therapeutics shares are trading higher on a rebound amid increased volatility in the stock, which sold off yesterday after the clinical trial setback.

RAPT shares are trading on a strong session volume of 11.01 million, compared to an average volume of 628.843K, as per data from Benzinga Pro.

However, certain analysts downgraded RAPT Therapeutics after the trial setback:

HC Wainwright downgraded RAPT Therapeutics from Buy to Neutral, noting that the FDA clinical …

Full story available on Benzinga.com

Visited 4 times, 1 visit(s) today